CD1D and systemic sclerosis: Depleting BAFF exhibits potential for SSc treatment via altering the balance of anti‐fibrotic IL‐10‐producing Bregs and pro‐fibrotic IL‐6‐producing effector B cells.[208] In addition, CD1d‐lipid presentation by CD1d+T2‐MZP Bregs mediates the differentiation of suppressive iNKT to downregulate Th1 and Th17 immune responses, partially depending on the IFN‐γ production.[212] Thus, Bregs‐mediated immune tolerance and inflammation inhibition provide new therapeutic avenues for chronic injury‐induced scar formation.